Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minBearish
Daily trend turns up above $38.35
Key levels
Resistance$40.95
Resistance$38.35
Support$36.11
Support$30.15
Latest news & SEC filings
AnalystTruist Securities keeps Hold rating on Immunovant, lifts price target to $33
AnalystWells Fargo keeps Overweight on Immunovant, lifts target to $47
All IMVT news →Immunovant develops antibody-based medicines for people with autoimmune conditions. Its lead candidate, IMVT-1402 (imeroprubart), targets the FcRn receptor to lower harmful IgG antibodies. The company runs studies in thyroid eye-related Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjogren's disease, and cutaneous lupus. It conducts research and trials across North America and other regions.
Based on the company's 10-K filed May 20, 2026.
Nasdaq · Healthcare
SEPT Low Target
$30.00
SEPT Mid Target
$46.50
SEPT High Target
$62.00
Analyst Consensus
$46.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMVT.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$37.07
12
Moat Score
NONE
2/9
Piotroski Score
28.3
Altman Z-Score
Insider Signal
SELLING
0 buys / 12 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Girao Tiago | officer | Sale | 6,606 | $188K | Oct 28, 2026 |
| Stout Jay S | officer | Sale | 2,595 | $75K | Oct 21, 2026 |
| Stout Jay S | officer | Sale | 2,213 | $71K | Oct 7, 2026 |
| Stout Jay S | officer | Sale | 1,596 | $51K | Oct 7, 2026 |
| Van Tuyl Christopher | officer | Sale | 1,327 | $43K | Oct 7, 2026 |
| Gloria Melanie | officer | Sale | 2,241 | $72K | Oct 7, 2026 |
| Venker Eric | director officer | Sale | 3,506 | $120K | Oct 2, 2026 |
| Venker Eric | director officer | Buy | 92,187 | $1.3M | Oct 1, 2026 |
| Venker Eric | director officer | Sale | 85,886 | $2.9M | Oct 1, 2026 |
| Van Tuyl Christopher | officer | Sale | 2,846 | $103K | Sep 23, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-1.47%
FCF Growth YoY
-8.2%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for IMVT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:31:48 | $36.75 | 1,000 | $$37K | MIDPOINT |
| 21:00:18 | $37.04 | 1,876 | $$69K | BUY |
| 21:00:18 | $37.04 | 2,965 | $$110K | BUY |
| 21:00:18 | $37.04 | 3,600 | $$133K | BUY |
| 21:00:18 | $37.04 | 1,795 | $$66K | BUY |
5 dark pool trades shown · $$416K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Immunovant, Inc. (IMVT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (6 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Immunovant, Inc. (IMVT) is at $36.53, down 1.38% (-$0.51) at the Nov 12, 2026 close.
Latest IMVT news — Nov 10, 2026: Truist Securities keeps Hold rating on Immunovant, lifts price target to $33 · Nov 10, 2026: Wells Fargo keeps Overweight on Immunovant, lifts target to $47
Immunovant shares rose 5.49% to close at $35.15 after the company reported that its drug met the primary endpoint in a trial of hard-to-treat rheumatoid arthritis, a bullish clinical catalyst. The stock also got a lift from a smaller-than-expected quarterly loss of 47 cents per share versus the 71 cents analysts projected.
The average analyst price target for IMVT is $46.50, ranging from $30 to $62, based on 6 analysts. Latest: JP Morgan maintains on Aug 4, 2026.
Analyst ratings for IMVT: 13 Buy, 4 Hold, 0 Sell — consensus Buy.
IMVT last reported on Nov 9, 2026: EPS -$0.47 vs -$0.71 expected — a beat of 33.8%.
IMVT does not currently pay a dividend.
Support: $36.11, $30.15, $28.38. Resistance: $38.35, $40.95, $42.92.
Insider activity: SELLING, 0 buys and 12 sells in the last 90 days.
Nov 10, 2026: Truist Securities keeps Hold rating on Immunovant, lifts price target to $33 · Nov 10, 2026: Wells Fargo keeps Overweight on Immunovant, lifts target to $47